JAZZ - Jazz Pharmaceuticals 2022 adjusted EPS guidance range includes consensus estimate

November, 09 2022 05:11 PM Jazz Pharmaceuticals plc

Jazz Pharmaceuticals ( NASDAQ: JAZZ ) updated full-year guidance includes an adjusted EPS estimate range that includes the consensus guidance.
The company is expecting adjusted EPS of $17.20 to $17.85 (consensus $17.30). It also raised the midpoint of its revenue guidance to $3.65B ($3.64B consensus).
In Q3 2022, adjusted net income rose ~42% to $370.4M compared to the prior-year period ($5.17 adjusted EPS vs. $4.20).
Revenue of ~$940.7M was a ~12% year-over-year increase. Jazz ( JAZZ ) beat on the bottom line , while the top line was in-line.
Sales of Xyrem and Xywav, the company's top selling drugs, both used for narcolepsy, rose ~11% to ~$512M.
Jazz ended the quarter with cash and cash equivalents of ~$839.4M, a ~42% increase from Dec. 31, 2021.
Check out why Seeking Alpha contributor ONeil Trader rates Jazz ( JAZZ ) a buy.

For further details see: